Company intelligence / Profile preview
OncoResponse
Houston, Texas, United Statesoncoresponse.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Phase 1 trial of OR502 (anti-LILRB2 antibody) showed excellent safety profile with no DLTs, SAEs or Grade ≥ 3 treatment-related AEs. Early efficacy signals in monotherapy included 2 PR and 9 SD (N=17) for a disease control rate of 65%. The company is proceeding with mini-cohorts in cutaneous melanoma and NSCLC[4][8].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesHumanized antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
MD Anderson Cancer CenterJust-Evotec Biologics
Beyond the preview
Go deeper on OncoResponse.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoResponse.